[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-356576-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-356576-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-and-predictive-potential-of-multiparametric-dynamic-whole-body-18f-fdg-pet-imaging-using-a-long-axial-field-of-view-lafov-system-for-first-line-chemo-immunotherapy-efficacy-in-advanced-non-small-cell-lung-cancer-profil-1-study-protocol","PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol","","Study protocol for the PROFIL-1 multicentre, prospective single-arm biomarker pilot evaluating whether multiparametric dynamic whole-body 18F-FDG PET parameters derived from a Long axial field-of-view (LAFOV-PET) scanner can predict and stratify outcomes of first-line chemo-immunotherapy in advanced non-small cell lung cancer without actionable genomic alterations. Up to 120 treatment-naïve patients will undergo baseline LAFOV-PET, with optional second dynamic imaging after induction. The primary endpoint is disease progression or death at one year assessed by RECIST v1.1.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-and-predictive-potential-of-multiparametric-dynamic-whole-body-18f-fdg-pet-imaging-using-a-long-axial-field-of-view-lafov-system-for-first-line-chemo-immunotherapy-efficacy-in-advanced-non-small-cell-lung-cancer-profil-1-study-protocol/356576/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-and-predictive-potential-of-multiparametric-dynamic-whole-body-18f-fdg-pet-imaging-using-a-long-axial-field-of-view-lafov-system-for-first-line-chemo-immunotherapy-efficacy-in-advanced-non-small-cell-lung-cancer-profil-1-study-protocol/356576.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-26","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main goal of the PROFIL-1 study protocol?","Question",{"text":63,"@type":64},"To determine whether 18F-FDG LAFOV-PET derived parameters have prognostic and predictive potential for outcomes of first-line chemo-immunotherapy in advanced NSCLC without actionable genomic alterations.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Who will be enrolled in PROFIL-1 and what imaging will be performed?",{"text":68,"@type":64},"Adult treatment-naïve advanced non-squamous or squamous NSCLC patients without AGAs eligible for first-line CT-IO will be recruited, undergoing baseline LAFOV-PET and an optional second dynamic LAFOV-PET after induction.",{"name":70,"@type":61,"acceptedAnswer":71},"What is the primary endpoint and how is it assessed?",{"text":72,"@type":64},"The primary endpoint is the rate of disease progression or death at one year, assessed by investigators using RECIST v1.1 criteria.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},356576,1790747830,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","OPEN ACCESS  \nCitation: Geier M, Amrane K, Bourhis D, Le Roux P-Y, Nguyen J, Dhamelincourt E, et al.(2026) PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol. PLoS One 21(4): e0345990. [https://](https://)[ ](https://)[doi.org/10.1371/journal.pone.0345990](doi.org/10.1371/journal.pone.0345990)  \nEditor: Carmelo Caldarella, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, ITALY  \nReceived: November 11, 2025  \nAccepted: March 7, 2026  \nPublished: April 3, 2026  \nCopyright: © 2026 Geier et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nData availability statement: No datasets were generated or analysed during the current study.  \nSTUDY PROTOCOL  \nPRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of  \nview (LAFOV) system for FIRST-line chemoimmunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol  \nMargaux Geier1,2*, Karim Amrane3, David Bourhis1,4, Pierre-Yves Le Roux1,4, Jessica Nguyen2, Estelle Dhamelincourt2, Renaud Descourt2, Gilles Quéré2, Marie Guegan2, Benjamin Besse5,6, Désirée Déandreis6,7, Florent Besson8, Sylvain Faure9, Nicolas Karakatsanis10, Pierre-Yves Salaun1,4, Mathieu Pavoine4, Vincent Bourbonne11,12, François Lucia11,12, Ronan Abgral1,4  \n1 Univ Brest, Inserm, UMR 1304, GETBO, Brest, France, 2 Department of Medical Oncology, Cancer & Imaging Institute, CHU La Cavale Blanche, University Hospital of Brest, Brest, France, 3 Department of Medical Oncology, CH Morlaix, Morlaix, France, 4 Department of Molecular Imaging and Theranostics, Cancer & Imaging Institute, CHU La Cavale Blanche, University Hospital of Brest, Brest, France,  \n5 Department of Medical Oncology, International Center for Thoracic Cancers (CICT), Gustave Roussy, Villejuif, France, 6 Paris-Saclay University, Paris, France, 7 Imaging Department, Nuclear Medicine Service, Gustave Roussy, Villejuif, France, 8 Department of Nuclear Medicine and Molecular Imaging, Paris-Saclay University, AP-HP, CHU Bicêtre, DMU SMART IMAGING, Le Kremlin-Bicêtre, Paris, France, 9 Laboratoire de Mathématique d’Orsay, CNRS, Université Paris-Saclay, Orsay City, France, 10 Department of Radiology, Weill Cornell Medical College, New York, New York, United States of America, 11 Radiation Oncology Department, University Hospital, Brest, France, 12 LaTIM, INSERM, UMR 1101, University of Brest, ISBAM, UBO, UBL, Brest, France  \n* [margaux.geier@chu-brest.fr](margaux.geier@chu-brest.fr)  \nAbstract  \nBackground  \nRevolution of chemo-immunotherapy (CT-IO) in the first-line treatment of metastatic non-small-cell lung cancers (NSCLC) without actionable genomic alterations (AGAs) has dramatically improved prognosis, providing long response in a subset of patients. Due to the highly heterogeneous nature of the disease, most of patients do not show long term benefit. Long axial field of view positron emission tomography (LAFOVPET) scanner is a new emerging system allowing dynamic whole-body imaging with higher sensitivity, representing unique opportunity for oncological applications. The aim of this study is to determine whether 18 F-fluorodeoxyglucose positron emission (18 F-FDG) LAFOV-PET derived parameters might have prognostic and predictive potential for CT-IO outcomes in NSCLC.  \nPLOS One | [https://doi.org/10.1371/journal.pone.0345990](https://doi.org/10.1371/journal.pone.0345990) April 3, 2026 1 / 17  \nAll relevant data from this study will be made available upon study completion.  \nFunding: The author(s) received no specific funding for this work.  \nCompeting interests: The authors h","cbCaikkklXYoeb4G","https://ap.wps.com/l/cbCaikkklXYoeb4G","pdf",951662,17,"English","# Abstract\n## Background\n## Methods\n## Clinical trial information\n## Introduction\n## Context","[{\"question\":\"What is the main goal of the PROFIL-1 study protocol?\",\"answer\":\"To determine whether 18F-FDG LAFOV-PET derived parameters have prognostic and predictive potential for outcomes of first-line chemo-immunotherapy in advanced NSCLC without actionable genomic alterations.\"},{\"question\":\"Who will be enrolled in PROFIL-1 and what imaging will be performed?\",\"answer\":\"Adult treatment-naïve advanced non-squamous or squamous NSCLC patients without AGAs eligible for first-line CT-IO will be recruited, undergoing baseline LAFOV-PET and an optional second dynamic LAFOV-PET after induction.\"},{\"question\":\"What is the primary endpoint and how is it assessed?\",\"answer\":\"The primary endpoint is the rate of disease progression or death at one year, assessed by investigators using RECIST v1.1 criteria.\"}]","PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocol | PDF",1790126030,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9d58796403af0af9f08081f3d69a48a9.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/befdf62b1f7084c52b93b423b6580815.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3b4a7e5d29e3427eed0d3902bb1dabe3.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0c4c720876f8c07323aabab1138387b.webp",980,1268]